EUVIMEDEUVIMED entdecken
Crossref

Reversing Immune Checkpoint Inhibitor–Associated Cardiotoxicity via Bioorthogonal Metabolic Engineering–Driven Extracellular Vesicle Redirecting

Miao Fan, Xing Zhang, Huifang Liu, Lanya Li, Fei Wang, Li Luo, Xiaohan Zhou, Xing-Jie Liang, Jinchao Zhang iD, Zhenhua Li iD

Advanced Materials · 2024-11 · 36 (45)

DOI: 10.1002/adma.202412340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 23.09.2024. Verfasst von Miao Fan und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Immune Checkpoint Inhibitors, Cardiotoxicity, Metabolic Engineering. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science Fund for Creative Research Groups of Nature Science Foundation of Hebei Province, Natural Science Foundation of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cardiotoxicity induced by immune checkpoint inhibitors (ICIs) is associated with high mortality rates. T cells play an important role in ICI‐induced cardiac injury. The inhibition of local T‐cell activity is considered an effective strategy for alleviating ICI‐related cardiotoxicity. Tumor‐derived extracellular vesicles (EVs) contribute to immunosuppression via PD‐L1 overexpression. In this study, a bioorthogonal metabolic engineering–driven EV redirecting (Biomeder) strategy for in situ engineered EVs with myocardial‐targeting peptides is developed. Accumulated tumor‐derived EV (TuEVs) reverses the immune environment in the heart by increasing PD‐L1 levels in cardiomyocytes and/or by directly inhibiting T‐cell activity. More importantly, it is found that the redirection of TuEVs further disrupts immunosuppression in tumors, which facilitates anti‐tumor activity. Thus, redirecting TuEVs to the heart simultaneously enhances the antitumor efficacy and safety of ICI‐based therapy. Furthermore, the Biomeder strategy is successfully expanded to prevent ICI‐induced type 1 diabetes. This Biomeder technique is a universal method for the treatment of various ICI‐related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesImmune Checkpoint InhibitorsCardiotoxicityMetabolic EngineeringB7-H1 AntigenAnimalsMiceHumansCell Line, TumorMyocytes, CardiacNeoplasmsT-LymphocytesDiabetes Mellitus, Type 1

Stichwörter der Autor:innen

ICI‐induced T1DICI‐induced cardiotoxicitybioorthogonal metabolic engineeringcardio‐oncologyextracellular vesicles

Substanzen

Immune Checkpoint InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China.
  • College of Chemistry & Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Chemical Biology…
  • College of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, China.
  • College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding, 071002, China.
  • CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, 100190, China.
  • Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Southern Medical University, Guangdong, 510515, China.

ORCID-Profile: Jinchao Zhang, Zhenhua Li

Förderung

  • National Natural Science Foundation of China
  • Science Fund for Creative Research Groups of Nature Science Foundation of Hebei Province
  • Natural Science Foundation of Hebei Province
  • Hebei Province Higher Education Science and Technology Research Project
  • Research and Innovation Team of Hebei University
  • Hebei Province Innovation Capability Enhancement Plan Project
  • China Postdoctoral Science Foundation
  • Hebei Province Science Foundation for postdoctoral

Zitieren

APA

Fan, M., Zhang, X., Liu, H., Li, L., Wang, F., Luo, L., Zhou, X., Liang, X. J., Zhang, J., & Li, Z. (2024). Reversing Immune Checkpoint Inhibitor–Associated Cardiotoxicity via Bioorthogonal Metabolic Engineering–Driven Extracellular Vesicle Redirecting. Advanced Materials, 36(45). https://doi.org/10.1002/adma.202412340

Vancouver

Fan M, Zhang X, Liu H, Li L, Wang F, Luo L, et al. Reversing Immune Checkpoint Inhibitor–Associated Cardiotoxicity via Bioorthogonal Metabolic Engineering–Driven Extracellular Vesicle Redirecting. Advanced Materials. 2024;36(45). doi:10.1002/adma.202412340

BibTeX
@article{Fan2024,
  author = {Fan, Miao and Zhang, Xing and Liu, Huifang and Li, Lanya and Wang, Fei and Luo, Li and Zhou, Xiaohan and Liang, Xing-Jie and Zhang, Jinchao and Li, Zhenhua},
  title = {Reversing Immune Checkpoint Inhibitor–Associated Cardiotoxicity via Bioorthogonal Metabolic Engineering–Driven Extracellular Vesicle Redirecting},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {45},
  doi = {10.1002/adma.202412340}
}
Kostenlos starten →